У нас вы можете посмотреть бесплатно Alzamend Neuro aiming to rapidly develop and market safe and effective treatments for Alzheimer's или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Alzamend Neuro Inc (NASDAQ:ALZN) CEO and director Stephan Jackman speaks to Proactive about the two therapeutics the company is currently working to transition targeting Alzheimer’s disease and psychiatric disorders from clinical/non-clinical stages and towards full commercialization. Jackman told Proactive that more than 6 million Americans suffer from Alzheimer's, with a similar number of suffering from bipolar disorder. More than 21 million people in the United States suffer from depression, while about 13 million are affected by post-traumatic stress disorder. "The patient population for this one product, our lead drug candidate, is a little over 43 million just in the United States," Jackman added. "Globally that's about 600 million people."